Multiple sclerosis symptom management

Expert Review of Neurotherapeutics

Volumn 7, Issue 9, 2007, Pages 1213-1222

  Boissy, Adrienne R ^a   Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Multidisciplinary care; Multiple sclerosis; Quality of life; Symptoms

Indexed keywords

BACLOFEN; CLONAZEPAM; GABAPENTIN; LIORESOL; PRIMIDONE; TIZANIDINE; UNCLASSIFIED DRUG;

BLADDER DYSFUNCTION; COGNITIVE DEFECT; DISABILITY; DISEASE COURSE; FATIGUE; HUMAN; MOOD DISORDER; MULTIPLE SCLEROSIS; PAIN; PHYSICAL PERFORMANCE; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SPASTICITY; TREMOR;

GAIT DISORDERS, NEUROLOGIC; HUMANS; MENTAL DISORDERS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN; URINARY BLADDER, NEUROGENIC;

EID: 34548824354     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.9.1213     Document Type: Review

References (84)

1. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
2. Multiple Sclerosis Therapeutics. Cohen JA, Rudick RA (Eds). Informa Healthcare, London, UK 773-870 (2007). •• Provides an extensive discussion of multiple sclerosis (MS) symptoms and disease management.
3. Stempein L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am. J. Phys. Med. Rehabil. 79(6), 536-541 (2000).
4. Sylvester A, Sadiq S. Long term use of intrathecal baclofen infusion in ambulatory patients with spasticity. Neurology 56, A26 (2001).
5. Bethoux F, Gogol D, Schwetz K, Kinkel RP. Use of a registry on intrathecal baclofen therapy in a large multiple sclerosis center: analysis of data on 82 patients and proposed changes. Poster 184. Arch. Phys. Med. Rehabil. 82(9), 1329 (2001). •• Provides a comprehensive overview of the clinical symptoms and management of spasticity in MS.
6. Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J. Neurol. Neurosurg. Psychiatr. 73(6), 705-709 (2002).
7. Patwardhan RV, Minagar A, Kelley RE, Nanda A. Neurosurgical treatment of multiple sclerosis. Neurol. Res. 28(3), 320-325 (2006).
8. Smyth MD, Peacock WJ. The surgical treatment of spasticity. Muscle Nerve 23(2), 153-163 (2000).
9. Bethoux F. Management of spasticity. In: Multiple Sclerosis Therapeutics. Cohen JA, Rudick RA (Eds). Informa Healthcare, London, UK 787-798 (2007).
10. Tranchant C, Bhatia K, Marsden C. Movement disorders in multiple sclerosis. Mov. Disord. 10, 418-423 (1995).
11. Fox RJ, Cohen JA. Multiple sclerosis: the importance of early recognition and treatment. Cleve. Clin. J. Med. 68, 157-171 (2001).
12. Geny C, Nguyen J, Pollin B et al. Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov. Disord. 11, 489-494 (1996).
13. Benabid AL, Pollak P, Gao D et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment for movement disorders. J. Neurosurg. 84, 203-214 (1996).
14. Herrera WG. Vestibular and other balance disorders in multiple sclerosis. Differential diagnosis of disequilibrium and topognostic localization. Neurol. Clin. 8(2), 407-420 (1990).
15. Carter S, Sciarra D, Merritt HH. The course of multiple sclerosis as determined by autopsy proven cases. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 28, 471-511 (1950).
16. Gass A, Steinke W, Schwartz A, Hennerici MG. High resolution magnetic resonance imaging in peripheral vestibular dysfunction in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 65(6), 945 (1998).
17. Thomke F, Hopf HC. Pontine lesions mimicking acute peripheral vestibulopathy. J. Neurol. Neurosurg. Psychiatr. 66(3), 340-349 (1999).
18. Frohman EM, Kramer PD, Dewey RB, Kramer L, Frohman TC. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult. Scler. 9(3), 250-255 (2003). • Characterizes vertigo as a result of benign peripheral paroxysmal vertigo versus MS and outlines strategies for treatment.
19. Frohman EM, Zhang H, Dewey RB et al. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 55(10), 1566-1569 (2000).
20. Cattaneo D, De Nuzzo C, Fascia T et al. Risks of falls in subjects with multiple sclerosis. Arch. Phys. Med. Rehabil. 83(6), 864-867 (2002).
21. Lord SE, Wade DT, Halligan PW. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin. Rehabil. 12(6), 477-486 (1998).
22. Gallien P, Nicolas B, Robineau S et al. Physical training and multiple sclerosis. Ann. Readapt. Med. Phys. 50(6), 373-376 (2007).
23. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41, 685-691 (1991). •• Comprehensive overview of the cognitive issues related to MS and the challenges in diagnosis.
24. Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J. Consult. Clin. Psychol. 53, 103-110 (1985).
25. Rao SM, Leo GJ, Ellington L et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41, 692-696 (1991). •• Comprehensive overview of the cognitive issues in MS and the profound impact of cognitive dysfunction on daily functioning.
26. Schultheis M, Garay E, DeLuca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 56, 1089-1094 (2001).
27. Schultheis M, Garay E, Millis S, DeLuca J. Motor vehicle crashes and violations among drivers with multiple sclerosis. Arch. Phys. Med. Rehabil. 83, 1175-1178 (2002).
28. Chipchase S, Lincoln N. Factors associated with carer strain in carers of people with multiple sclerosis. Disabil. Rehabil. 23(17), 768-776 (2001).
29. Beatty W, Goodkin D, Hertsgaard D, Monson N. Clinical and demographic predictors of cognitive performance in multiple sclerosis. Do diagnostic type, disease duration, and disability matter? Arch. Neurol. 47, 305-308 (1990).
30. Rovaris M, Filippi M, Falautano M et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 50, 1601-1608 (1998).
31. Berg D, Maurer M, Warmuth-Metz M, Rieckmann P, Becker G. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch. Neurol. 57, 1289-1292 (2000).
32. Zivadinov R, De Masi R, Nasuelli D et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting MS. Neuroradiology 43, 272-278 (2001).
33. Beatty W, Goodkin D. Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination. Arch. Neurol. 47(3), 297-301 (1990).
34. Swirsky-Sacchetti T, Field H, Mitchell D et al. The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J. Clin. Psychol. 48(6), 779-786 (1992).
35. Aupperle R, Beatty W, Shelton Fde N, Gontkovsky S. Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult. Scler. 8(5), 382-389 (2002).
36. Greene Y, Tariot P, Wishart H et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis abd associated cognitive impairments. J. Clin. Psychopharmacol. 20, 350-356 (2000).
37. Krupp L, Christodoulou C, Melville P et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63(9), 1579-1585 (2004).
38. Sadovnick AD, Remick RA, Allen J et al. Depression and multiple sclerosis. Neurology 46, 628-632 (1996).
39. Edwards L, Constantinescu C. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis center. Mult. Scler. 10, 575-581 (2004).
40. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult. Scler. 13(1), 67-72 (2007).
41. Wells K, Golding J, Burnam M. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am. J. Psychiatr. 145, 976-981 (1988).
42. Sadovnick A, Eisen K, Ebers G, Paty D. Cause of death in patients attending multiple sclerosis clinics. Neurology 41, 1193-1196 (1991).
43. Riudavets MA, Colegial C, Rubio A et al. Causes of unexpected death in patients with multiple sclerosis: a forensic study of 50 cases. Am. J. Forensic Med. Pathol. 26(3), 244-249 (2005).
44. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 59(5), 674-678 (2002).
45. Taylor M, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J. Affect. Disord. 88, 241-254 (2005).
46. Jefferson J, Pradko J, Muir K. Buproprion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther. 27, 1685-1695 (2005).
47. Wernicke J, Gahimer J, Yalcin I et al. Safety and adverse event profile of duloxetine. Expert Opin. Drug Saf. 4(6), 987-993 (2005).
48. Foster H Jr. Bladder symptoms and multiple sclerosis. Mult. Scler. Quart. Rep. 21, 5-8 (2002).
49. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. 81, 801-810 (1998).
50. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. 78, 687-695 (2003).
51. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65(1), 37-41 (2005).
52. de Seze M, Wiart L, de Seze MP et al. Reiterated intravesical instillation of capsaicin in neurogenic detrusor hyperreflexia: a 5-years experience of 100 instillations. Ann. Readapt. Med. Phys. 44(8), 514-524 (2001).
53. Smith CP, Somogyi GT, Chancellor MB. Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction. Curr. Urol. Rep. 3(5), 382-387 (2002).
54. Chia YW, Fowler CJ, Kamm MA et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J. Neurol. 242(2), 105-108 (1995).
55. Zorzon M, Zivadinov R, Bosco A et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult. Scler. 5(6), 418-427 (1999).
56. Hennessey A, Robertson N, Swingler R, Compston D. Urinary, faecal and sexual sysfunction in patients with multiple sclerosis. J. Neurol. 246, 1027-1032 (1999).
57. DasGupta R, Fowler C. Bladder, bowel and sexual dysfunction in multiple sclerosis. Management strategies. Drugs 63, 153-166 (2003).
58. Wiesel P, Norton C, Roy A et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 69, 240-243 (2000).
59. Miller AE, Bourdette DN, Cohen JA et al. Multiple Sclerosis. Clinical features of multiple sclerosis. Continuum 5, 35-49 (1999). • Outlines the clinical presentations of MS.
60. Hellstrom WJ, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61(4 Suppl. 1), 8-14 (2003).
61. Skoumal R, Chen J, Kula K et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur. Urol. 46(3), 362-369 (2004).
62. Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD. Efficacy of sildenafil in the treatment of female sexual dysfunction. J. Urol. 171, 1189-1193 (2004).
63. Sipski M, Rosen R, Alexander C, Hamer R. Sildefanil effects on sexual and cardiovascular response in women with spinal cord injury. Urology 55, 812-815 (2000).
64. Guidelines MSCfCP. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC, USA 1-46 (1998).
65. Codella M, Rocca MA, Colombo B et al. A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. J. Neurol. 249, 535-537 (2002).
66. Mainero C, Faroni J, Gasperini C et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J. Neurol. 246, 454-458 (1999).
67. Fleming W, Pollack C. Sleep disorders in multiple sclerosis. Semin. Neurol. 25, 64-68 (2005).
68. Tachibana N, Howard RS, Hirsch NP et al. Sleep problems in multiple sclerosis. Eur. Neurol. 34, 320-323 (1994).
69. Krupp L, Coyle P, Doscher C et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 47(5), 1956-1961 (1995).
70. Pucci E, Branas P, D'Amico R et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst. Rev. 1, CD002818 (2007).
71. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatr. 67(4), 554-566 (2006).
72. Provigil® (Modafinil), package insert. Cephalon, Inc. West Chester, PA, USA (2004).
73. Challman TD, Lipsky JJ. Methyphenidate: its pharmacology and uses. Mayo Clin. Proc. 75(7), 711-721 (2000).
74. Goodman AD, Cohen JA, Cross A et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult. Scler. 13(3), 357-368 (2007).
75. Thompson A. Multiple sclerosis: symptomatic management. J. Neurol. 243, 559-565 (1996).
76. Garg N, Weinstock-Guttman W. Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis. In: Multiple Sclerosis Therapeutics. Cohen JA, Rudick RA (Eds). Informa Healthcare, London, UK 845-862 (2007). •• Highlights the various types of paroxysmal disorders in MS and specifically outlines management approaches and potential medical therapeutics.
77. McQuay H, Carroll D, Jadad A, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br. Med. J. 311, 1047-1052 (1995).
78. Khan O. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 51, 611-614 (1998).
79. Moeen U, Zvartau-Hind M, Gilani A, Lisak R, Khan O. Topiramate relieves refractory trigeminal neuralgia in multiple sclerosis patients. Neurology 54(Suppl. 3), A60 (2000) (Abstract).
80. Besson J. The neurobiology of pain. Lancet 353, 1610-1615 (1999).
81. Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60(11), 1524-1534 (2003).
82. National Multiple Sclerosis Society www.nmss.org
83. American Academy of Neurology www.aan.com
84. Current ongoing trials in multiple sclerosis http://clinicaltrials.org